TMCnet News
DayTwo Secures $12.0 Million Series A Financing RoundTEL AVIV, Israel and SAN FRANCISCO, June 27, 2017 /PRNewswire/ -- DayTwo, a leader in microbiome-health management, announced today it has completed a $12.0 million Series A round of financing through Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Seventure Partners' Health for Life Capital fund, Mayo Clinic, co-founder Marius Nacht, and other private investors. The investment brings DayTwo's total funding to $17.0 million, and will help the company to broaden and deepen its lead in evidence-based, clinically proven and actionable science of the gut microbiome. Proceeds from the financing will be used to expand the company's product, engineering, and data science teams in Tel Aviv, Israel and San Francisco, California. In addition, DayTwo will deepen its clinical research with the Mayo Clinic and other gut-microbiome clinical research partners. The Series A financing builds on an exceptional year for DayTwo, which saw a rapid growth in customers, key executive appointments, and market momentum in the areas of gut-microbiome-science, personalized nutrition, and diabetes and prediabetes management. DayTwo is the first company to develop a method to accurately predict an individual's glycemic response to specific foods and food combinations using an individual's microbiome and other clinical factors. This evidence-based approach to nutrition is what enables DayTwo to bring personalized nutrition to market, and make personalized nutrition a reality for millions of people today. "This ability to go beyond the informational offerings in the market, which are neither evidence-based, clinically proven, or actionable, makes DayTwo different and special. DayTwo will help people act upon a healthier, personalized diet, based on accurately predicting postprandial glycemic response," said Nicholas Chia, professor of Biophysics & Microbiome at the Mayo Clinic in Rochester, Minnesota. The DayTwo approach to health and nutrition recognizes that every individual has a unique gut microbiome and may respond very differently to the same food or food combinations. Day Two is currently the only offering in the market that can bring a personalized diet and nutrition plan to individuals, based on accurately predicting their own glycemic response. As postprandial glycemic response (post-meal blood sugar) is an independent risk factor for multiple diseases and affects weight gain and fat storage, maintaining normal blood glucose levels requires a nutrition plan that is tailored to the individual. DayTwo's science is the only offering of its kind in the marketplace today. DayTwo's personalized nutrition offering is based on the original research led by Professors Eran Segal and Eran Elinav from the Weizmann Institute of Science in Israel, and published in the scientific journal Cell. Segal and Elinav found that by profiling an individual's gut microbiome and leveraging machine learning, thy can accurately predict an individual's post-meal blood sugar response for unique foods and food combinations. This scientific and machine learning breakthrough has made personalized nutrition a reality today, and enables DayTwo to fulfill its mission to improve the health and wellbeing of millions, including diabetics and prediabetics, worldwide. For consumers, DayTwo offers a cloud-based, first-of-its-kind, proprietary diet and nutrition planner, that enables individuals to get personalized scores for specific foods and food combinations based on their own gut-microbiome profile and other personal parameters. For clinicians and health practitioners, DayTwo brings actionable insights for diet and nutrition to the care plans and meal plans of their patients; brings ease and convenience to adherence to a healthy diet; and provides an additional path for clinicians and their patients to stay connected. For nutrition, microbiome, weight-management, and meal planning businesses, DayTwo offers an API to access the DayTwo platform-as-a-service to provide predictive glycemic response scores for specific foods and food combinations. "We've just scratched the surface of how powerful the microbiome is to support personalized diet, nutrition, and chronic condition management, to enable our customers to have the ability to live a full, happy and healthy lifestyle," says DayTwo Chief Executive Officer Lihi Segal. "DayTwo has brought actionable, evidence-based science down to a mobile app, to make personalized nutrition easy and convenient for the first time. This enables DayTwo to impact the lives of hundreds of millions of people who struggle with diet and nutrition-related health risks every day," added Segal. "Having the financial support and domain expertise of JJDC, Seventure, co-founder Marius Nacht and our Israeli private equity investor group will enable us to execute our vision even more rapidly and broadly – with consumers, practitioners, health centers, and medical device partners." Isabelle de Cremoux, CEO and Managing partner of Seventure Partners, added "Our investment in DayTwo fits very well into the focus of Health for Life Capital, as DayTwo acts on precise knowledge of an individual's microbiome. DayTwo is positioned at the interface between nutrition and health, with an easy-to-use app which provides precisely tailored advice for each individual's dietary needs." About DayTwo About Johnson & Johnson Innovation – JJDC, Inc. About Seventure Partners
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/daytwo-secures-120-million-series-a-financing-round-300480088.html SOURCE DayTwo |